Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
Key Points
Sphera Funds added 374,847 shares of Syndax Pharmaceuticals in the fourth quarter.
The quarter-end position value rose by $10.06 million, reflecting both trading and price movement.
The post-trade holding stood at 762,563 shares valued at $16.02 million.
- 10 stocks we like better than Syndax Pharmaceuticals ›
On February 17, 2026, Sphera Funds Management Ltd. disclosed a purchase of 374,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $6.54 million trade based on quarterly average pricing.
What happened
According to its SEC filing dated February 17, 2026, Sphera Funds Management Ltd. bought 374,847 additional shares of Syndax Pharmaceuticals, bringing its total to 762,563 shares. The estimated value of the shares acquired in the fourth quarter was $6.54 million, based on the period’s average closing price. The quarter-end value of the position increased by $10.06 million, a figure that includes both new purchases and changes in the stock price.
What else to know
- The buy increased Syndax Pharmaceuticals to about 3% of Sphera Funds Management Ltd.'s 13F reportable assets under management.
- Top holdings after the filing:
- NYSE:TEVA: $35.07 million (7.4% of AUM)
- NASDAQ:BIIB: $16.67 million (3.5% of AUM)
- NASDAQ:MLYS: $16.29 million (3.4% of AUM)
- NASDAQ:SNDX: $16.02 million (3.4% of AUM)
- NASDAQ:NVMI: $15.71 million (3.3% of AUM)
- As of Friday, shares were priced at $23.99, up 83% over the past year and well outperforming the S&P 500’s roughly 20% gain in the same period.
Company overview
| Metric | Value |
|---|---|
| Price (as of Thursday) | $23.99 |
| Market Capitalization | $2.1 billion |
| Revenue (TTM) | $172.4 million |
| Net Income (TTM) | ($285.4 million) |
Company snapshot
- Syndax Pharmaceuticals develops oncology therapeutics, including SNDX-5613 for acute myeloid leukemia and axatilimab for chronic graft versus host disease.
- It targets healthcare providers, research institutions, and pharmaceutical partners focused on cancer and immunology treatments.
Syndax Pharmaceuticals, Inc. is a biotechnology company specializing in the development of therapies for cancer. The company's strategy centers on the commercialization of drugs, advancing its lead candidates through clinical trials, and forming strategic collaborations to accelerate commercialization.
What this transaction means for investors
Commercial traction is one of the clearest signals that a biotech company may be transitioning from a speculative clinical story into a real operating business, and that shift is showing up at Syndax Pharmaceuticals.
The company now has two approved therapies contributing to revenue growth. Revuforj, its first-in-class menin inhibitor for certain acute leukemia patients, generated $44.2 million in fourth-quarter net revenue (up 38% sequentially) and $124.8 million for the full year as adoption accelerated following its FDA approval. Meanwhile, Niktimvo, a treatment for chronic graft-versus-host disease developed with Incyte, delivered $151.6 million in full-year net sales across the collaboration.
Combined, those launches helped drive total revenue to $172.4 million in 2025, marking a sharp step up from the early commercialization phase the company was in only a year earlier, when it posted $23.7 million in revenue. Shares have surged more than 80% thanks to the commercial momentum, including close to 15% this year alone.
Should you buy stock in Syndax Pharmaceuticals right now?
Before you buy stock in Syndax Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Syndax Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $508,607!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,122,746!*
Now, it’s worth noting Stock Advisor’s total average return is 933% — a market-crushing outperformance compared to 188% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 13, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool recommends Biogen and Mineralys Therapeutics. The Motley Fool has a disclosure policy.
Recommended Articles
